文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

使用载脂蛋白A2亚型血液检测对导管内乳头状黏液性肿瘤的恶性潜能进行风险分层。

Risk Stratification for Malignant Potential of Intraductal Papillary Mucinous Neoplasms Using the Apolipoprotein-A2 Isoforms Blood Test.

作者信息

Hasegawa Yuta, Itokawa Norio, Kashiro Ayumi, Kitamura Michika, Nagashima Kengo, Suzuki Kenta, Higashi Tetsuyuki, Shioda-Koyano Kaori, Ono Hiroki, Kawano Tadamichi, Yoshida Yuji, Okubo Tomomi, Arai Taeang, Hayama Korenobu, Kaneko Keiko, Atsukawa Masanori, Takeuchi Keiko, Futagami Seiji, Iwakiri Katsuhiko, Honda Kazufumi

机构信息

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan.

Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

出版信息

Clin Transl Gastroenterol. 2025 May 12;16(6):e00856. doi: 10.14309/ctg.0000000000000856. eCollection 2025 Jun 1.

DOI:10.14309/ctg.0000000000000856
PMID:40358401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12180817/
Abstract

INTRODUCTION: High-risk stigmata (HRS) and worrisome features (WFs) are imaging findings that reflect malignant potential of intraductal papillary mucinous neoplasms (IPMNs). The aim of this study was to determine the potential utility of stratifying malignant potential of IPMNs using apolipoprotein-A2 isoforms (apoA2-i) as a blood biomarker. METHODS: A total of 212 patients with IPMNs diagnosed by either magnetic resonance cholangiopancreatography or contrast-enhanced computed tomography, and endoscopic ultrasound were retrospectively enrolled. ApoA2-i and CA19-9 of all patients and 295 healthy individuals were measured. The distributions of apoA2-i and CA19-9 were analyzed in association with the malignant potential evaluated by imaging. RESULTS: In 212 patients with IPMN, 17 had HRS (HRS group), 70 had WFs (WF group), and 125 had no endoscopic ultrasound findings of HRS or WFs (non-WF group). The median of the apoA2-i Index in the HRS, WF, non-WF, and healthy groups were 57.7, 72.4, 87.5, and 87.9 μg/mL, respectively, with significantly lower levels in the HRS and WF groups ( P < 0.001). By contrast, CA19-9 showed no significant difference among the 4 groups. The area under the curve of the apoA2-i Index to differentiate patients in the HRS and WF groups from the non-WF group was significantly higher than that of the CA19-9 (0.676 vs 0.554, P = 0.029). DISCUSSION: The diagnostic performance of apoA2-i for detecting IPMN with malignant potential was superior to that of CA19-9. The apoA2-i Index could serve as a useful biomarker for risk stratification and surveillance of IPMNs.

摘要

引言：高危征象（HRS）和可疑特征（WFs）是反映导管内乳头状黏液性肿瘤（IPMNs）恶性潜能的影像学表现。本研究的目的是确定使用载脂蛋白A2异构体（apoA2-i）作为血液生物标志物对IPMNs恶性潜能进行分层的潜在效用。 方法：回顾性纳入212例经磁共振胰胆管造影或对比增强计算机断层扫描及内镜超声诊断为IPMNs的患者。测量所有患者及295名健康个体的apoA2-i和CA19-9。分析apoA2-i和CA19-9的分布与影像学评估的恶性潜能之间的关系。 结果：212例IPMN患者中，17例有HRS（HRS组），70例有WFs（WF组），125例内镜超声未发现HRS或WFs（非WF组）。HRS组、WF组、非WF组和健康组的apoA2-i指数中位数分别为57.7、72.4、87.5和87.9μg/mL，HRS组和WF组水平显著较低（P<0.001）。相比之下，CA19-9在4组之间无显著差异。apoA2-i指数区分HRS组和WF组患者与非WF组患者的曲线下面积显著高于CA19-9（0.676对0.554，P=0.029）。 讨论：apoA2-i检测具有恶性潜能的IPMN的诊断性能优于CA19-9。apoA2-i指数可作为IPMNs风险分层和监测的有用生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/ae1471a34dfd/ct9-16-e00856-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/50a53c1c8646/ct9-16-e00856-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/e55b705c7a8b/ct9-16-e00856-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/095b1f9805da/ct9-16-e00856-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/13c86dc0ab8e/ct9-16-e00856-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/42d8655ddf5f/ct9-16-e00856-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/ae1471a34dfd/ct9-16-e00856-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/50a53c1c8646/ct9-16-e00856-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/e55b705c7a8b/ct9-16-e00856-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/095b1f9805da/ct9-16-e00856-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/13c86dc0ab8e/ct9-16-e00856-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/42d8655ddf5f/ct9-16-e00856-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf89/12180817/ae1471a34dfd/ct9-16-e00856-g006.jpg

相似文献

[1]
Risk Stratification for Malignant Potential of Intraductal Papillary Mucinous Neoplasms Using the Apolipoprotein-A2 Isoforms Blood Test.

Clin Transl Gastroenterol. 2025-5-12

[2]
Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review.

Pancreatology. 2024-2

[3]
Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.

Int J Cancer. 2022-3-1

[4]
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study.

Lancet Gastroenterol Hepatol. 2025-7

[5]
Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis.

Clin Gastroenterol Hepatol. 2017-3-22

[6]
Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis.

Cancer Treat Rev. 2025-7

[7]
Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis.

Clin Gastroenterol Hepatol. 2023-6

[8]
Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas.

Surgery. 2018-2-14

[9]
Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.

PLoS One. 2016-5-12

[10]
Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis.

Eur J Surg Oncol. 2025-7

本文引用的文献

[1]
International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas.

Pancreatology. 2024-3

[2]
Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms.

Cancer Biomark. 2022

[3]
Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.

Int J Cancer. 2022-3-1

[4]
Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?

Pancreatology. 2020-10

[5]
Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.

Gastroenterology. 2019-8-29

[6]
Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes.

Biomed Res Int. 2019-4-4

[7]
Precursor Lesions of Pancreatic Cancer.

Oncol Res Treat. 2018-9-28

[8]
European evidence-based guidelines on pancreatic cystic neoplasms.

Gut. 2018-3-24

[9]
Serum apolipoprotein A2 isoforms in autoimmune pancreatitis.

Biochem Biophys Res Commun. 2018-3-11

[10]
Progression of Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size.

Gastroenterology. 2017-10-23

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索